IND Ready Pipeline Navigen leverages non-dilutive funding to advance academia-sourced technologies to IND-enabling stages, with two programs approaching IND filing within a year. This creates sales opportunities for pharma/biotech partners to co-fund or license these assets to accelerate their own IND timelines.

Ready to License The near-term pre-IND programs represent ready-to-license assets attractive to large pharma seeking external innovation at an early stage. BD play: licensing deals, co-development, or milestone-based partnerships to bring programs to IND.

Lean Development As a small organization, Navigen can offer flexible, cost-efficient development services and scalable collaboration models for early-stage pharmacology, DMPK, and IND-enabling work.

Academia Access Navigen's model of sourcing technologies from academia provides access to novel mechanisms and potential tech-transfer opportunities, appealing to partners seeking diversified, academically sourced pipelines.

Regional Edge Based in Salt Lake City with proven non-dilutive funding accomplishments, Navigen offers a credible path for regional collaborations, early-stage discovery partnerships, and licensing opportunities ahead of broader internal programs.